Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
309
USD
|
+2.64%
|
|
+0.23%
|
+9.17%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,239
|
10,290
|
25,209
|
15,860
|
23,304
|
25,551
|
-
|
-
|
Enterprise Value (EV)
1 |
9,018
|
9,797
|
29,891
|
20,223
|
26,700
|
27,842
|
26,681
|
25,436
|
P/E ratio
|
25.4
x
|
31.7
x
|
138
x
|
31.7
x
|
38.3
x
|
31.2
x
|
25.7
x
|
22.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.29
x
|
3.68
x
|
4.6
x
|
2.05
x
|
2.87
x
|
2.96
x
|
2.75
x
|
2.57
x
|
EV / Revenue
|
3.21
x
|
3.5
x
|
5.45
x
|
2.61
x
|
3.29
x
|
3.22
x
|
2.87
x
|
2.56
x
|
EV / EBITDA
|
18.2
x
|
20.6
x
|
30.8
x
|
13.7
x
|
15.8
x
|
15.1
x
|
13.2
x
|
11.6
x
|
EV / FCF
|
24.9
x
|
19
x
|
40.6
x
|
48
x
|
26.2
x
|
23.5
x
|
18.8
x
|
16.6
x
|
FCF Yield
|
4.01%
|
5.28%
|
2.46%
|
2.08%
|
3.82%
|
4.25%
|
5.32%
|
6.01%
|
Price to Book
|
5.71
x
|
5.56
x
|
3.13
x
|
1.87
x
|
2.53
x
|
2.53
x
|
2.3
x
|
2.07
x
|
Nbr of stocks (in thousands)
|
53,641
|
52,775
|
81,398
|
81,645
|
82,327
|
82,684
|
-
|
-
|
Reference price
2 |
172.2
|
195.0
|
309.7
|
194.2
|
283.1
|
309.0
|
309.0
|
309.0
|
Announcement Date
|
19/02/20
|
24/02/21
|
22/02/22
|
22/02/23
|
21/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,806
|
2,797
|
5,481
|
7,741
|
8,120
|
8,641
|
9,282
|
9,943
|
EBITDA
1 |
495
|
475.7
|
970
|
1,479
|
1,694
|
1,848
|
2,017
|
2,189
|
EBIT
1 |
433.4
|
409.6
|
655
|
1,373
|
1,568
|
1,714
|
1,871
|
2,039
|
Operating Margin
|
15.45%
|
14.64%
|
11.95%
|
17.74%
|
19.31%
|
19.83%
|
20.16%
|
20.5%
|
Earnings before Tax (EBT)
1 |
427
|
381.2
|
196.7
|
567.9
|
624.5
|
948.4
|
1,137
|
1,275
|
Net income
1 |
374
|
332.3
|
153.2
|
505.3
|
612.3
|
820.2
|
1,000
|
1,139
|
Net margin
|
13.33%
|
11.88%
|
2.79%
|
6.53%
|
7.54%
|
9.49%
|
10.77%
|
11.45%
|
EPS
2 |
6.790
|
6.150
|
2.250
|
6.130
|
7.400
|
9.891
|
12.03
|
13.77
|
Free Cash Flow
1 |
361.9
|
516.9
|
735.4
|
421.2
|
1,020
|
1,183
|
1,420
|
1,528
|
FCF margin
|
12.9%
|
18.48%
|
13.42%
|
5.44%
|
12.57%
|
13.7%
|
15.3%
|
15.37%
|
FCF Conversion (EBITDA)
|
73.12%
|
108.66%
|
75.82%
|
28.47%
|
60.23%
|
64.03%
|
70.41%
|
69.81%
|
FCF Conversion (Net income)
|
96.77%
|
155.54%
|
480.07%
|
83.35%
|
166.63%
|
144.29%
|
142.02%
|
134.22%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/02/20
|
24/02/21
|
22/02/22
|
22/02/23
|
21/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1,885
|
1,902
|
1,935
|
1,942
|
1,962
|
1,979
|
2,020
|
2,055
|
2,066
|
2,090
|
2,138
|
2,190
|
2,226
|
2,252
|
2,300
|
EBITDA
1 |
332.5
|
340.6
|
354.3
|
379.6
|
405
|
399.1
|
414.2
|
432.5
|
448.2
|
444
|
453.3
|
468.3
|
481.6
|
486
|
494.8
|
EBIT
1 |
192.9
|
314
|
328.6
|
352.7
|
377.8
|
254
|
209.5
|
401.1
|
414.4
|
294.9
|
420.1
|
434.8
|
447.3
|
450.3
|
461.1
|
Operating Margin
|
10.23%
|
16.51%
|
16.98%
|
18.16%
|
19.25%
|
12.84%
|
10.37%
|
19.52%
|
20.06%
|
14.11%
|
19.65%
|
19.86%
|
20.09%
|
20%
|
20.05%
|
Earnings before Tax (EBT)
1 |
91.77
|
126
|
130.8
|
182.2
|
128.8
|
131.3
|
125.2
|
181.7
|
186.3
|
215.8
|
227.3
|
250.6
|
275.3
|
275.2
|
279.2
|
Net income
1 |
76.47
|
112
|
115.7
|
160.2
|
117.4
|
116.7
|
115.6
|
163.7
|
216.4
|
187.4
|
193.5
|
218.6
|
234.9
|
235.8
|
242.9
|
Net margin
|
4.06%
|
5.89%
|
5.98%
|
8.25%
|
5.99%
|
5.9%
|
5.72%
|
7.96%
|
10.47%
|
8.97%
|
9.05%
|
9.98%
|
10.55%
|
10.47%
|
10.56%
|
EPS
2 |
0.9200
|
1.360
|
1.410
|
1.940
|
1.420
|
1.410
|
1.400
|
1.970
|
2.600
|
2.250
|
2.350
|
2.609
|
2.804
|
2.833
|
2.933
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/02/22
|
27/04/22
|
27/07/22
|
02/11/22
|
22/02/23
|
26/04/23
|
26/07/23
|
25/10/23
|
21/02/24
|
24/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
4,682
|
4,364
|
3,396
|
2,291
|
1,130
|
-
|
Net Cash position
1 |
220
|
494
|
-
|
-
|
-
|
-
|
-
|
115
|
Leverage (Debt/EBITDA)
|
-
|
-
|
4.827
x
|
2.949
x
|
2.004
x
|
1.24
x
|
0.5601
x
|
-
|
Free Cash Flow
1 |
362
|
517
|
735
|
421
|
1,020
|
1,183
|
1,420
|
1,528
|
ROE (net income / shareholders' equity)
|
25.2%
|
19.2%
|
13.4%
|
11.7%
|
6.9%
|
12.6%
|
13.4%
|
13.6%
|
ROA (Net income/ Total Assets)
|
14.2%
|
10.5%
|
6.4%
|
5.6%
|
3.58%
|
6.82%
|
7.44%
|
7.86%
|
Assets
1 |
2,631
|
3,171
|
2,394
|
9,017
|
17,088
|
12,025
|
13,450
|
14,484
|
Book Value Per Share
2 |
30.20
|
35.10
|
98.90
|
104.0
|
112.0
|
122.0
|
134.0
|
149.0
|
Cash Flow per Share
2 |
7.590
|
10.70
|
12.40
|
6.830
|
14.00
|
15.00
|
18.90
|
20.20
|
Capex
1 |
50.6
|
51.1
|
93.8
|
142
|
141
|
174
|
183
|
193
|
Capex / Sales
|
1.8%
|
1.83%
|
1.71%
|
1.84%
|
1.73%
|
2.02%
|
1.97%
|
1.94%
|
Announcement Date
|
19/02/20
|
24/02/21
|
22/02/22
|
22/02/23
|
21/02/24
|
-
|
-
|
-
|
Average target price
354.1
USD Spread / Average Target +14.60% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.17% | 25.55B | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B | | +19.33% | 11.64B |
Other Biotechnology & Medical Research
|